228 related articles for article (PubMed ID: 18049024)
1. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H
Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
[TBL] [Abstract][Full Text] [Related]
2. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
[TBL] [Abstract][Full Text] [Related]
3. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Tan F; Mukherjee JJ; Lee KO; Lim P; Liew CF
Singapore Med J; 2010 Feb; 51(2):151-6. PubMed ID: 20358155
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
6. [Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Goicolea I; Fernández González R; Piniés J; Garrido J; Martínez JM; Armenteros S; Moreno Carretero E
Nefrologia; 2002; 22(2):170-8. PubMed ID: 12085418
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Lim SC; Koh AF; Goh SK; Chua CL; Heng BL; Subramaniam T; Sum CF
Diabetes Obes Metab; 2007 Jul; 9(4):477-82. PubMed ID: 17587389
[TBL] [Abstract][Full Text] [Related]
8. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
10. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
11. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
12. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
Shigihara T; Sato A; Hayashi K; Saruta T
Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
Kidney Int; 2002 Jul; 62(1):192-8. PubMed ID: 12081578
[TBL] [Abstract][Full Text] [Related]
17. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic management of diabetic nephropathy.
Vivian EM; Rubinstein GB
Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
Dragović T; Ajdinović B; Hrvacević R; Ilić V; Magić Z; Andelković Z; Kocev N
Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
